• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PLoS Pathog . Exposure modality influences viral kinetics but not respiratory outcome of COVID-19 in multiple nonhuman primate species

tetano

Editor, Senior Moderator
PLoS Pathog


. 2022 Jul 5;18(7):e1010618.
doi: 10.1371/journal.ppat.1010618. Online ahead of print.
Exposure modality influences viral kinetics but not respiratory outcome of COVID-19 in multiple nonhuman primate species


Alyssa C Fears[SUP] 1 2 [/SUP], Brandon J Beddingfield[SUP] 1 [/SUP], Nicole R Chirichella[SUP] 1 [/SUP], Nadia Slisarenko[SUP] 1 [/SUP], Stephanie Z Killeen[SUP] 1 [/SUP], Rachel K Redmann[SUP] 1 [/SUP], Kelly Goff[SUP] 1 [/SUP], Skye Spencer[SUP] 1 [/SUP], Breanna Picou[SUP] 1 [/SUP], Nadia Golden[SUP] 1 [/SUP], Cecily C Midkiff[SUP] 1 [/SUP], Duane J Bush[SUP] 3 [/SUP], Luis M Branco[SUP] 3 [/SUP], Matthew L Boisen[SUP] 3 [/SUP], Hongmei Gao[SUP] 4 [/SUP], David C Montefiori[SUP] 4 [/SUP], Robert V Blair[SUP] 1 [/SUP], Lara A Doyle-Meyers[SUP] 1 5 [/SUP], Kasi Russell-Lodrigue[SUP] 1 [/SUP], Nicholas J Maness[SUP] 1 6 [/SUP], Chad J Roy[SUP] 1 6 [/SUP]



Affiliations

Abstract

The novel coronavirus SARS-CoV-2 emerged in late 2019, rapidly reached pandemic status, and has maintained global ubiquity through the emergence of variants of concern. Efforts to develop animal models have mostly fallen short of recapitulating severe disease, diminishing their utility for research focusing on severe disease pathogenesis and life-saving medical countermeasures. We tested whether route of experimental infection substantially changes COVID-19 disease characteristics in two species of nonhuman primates (Macaca mulatta; rhesus macaques; RM, Chlorocebus atheiops; African green monkeys; AGM). Species-specific cohorts were experimentally infected with SARS-CoV-2 by either direct mucosal (intratracheal + intranasal) instillation or small particle aerosol in route-discrete subcohorts. Both species demonstrated analogous viral loads in all compartments by either exposure route although the magnitude and duration of viral loading was marginally greater in AGMs than RMs. Clinical onset was nearly immediate (+1dpi) in the mucosal exposure cohort whereas clinical signs and cytokine responses in aerosol exposure animals began +7dpi. Pathologies conserved in both species and both exposure modalities include pulmonary myeloid cell influx, development of pleuritis, and extended lack of regenerative capacity in the pulmonary compartment. Demonstration of conserved pulmonary pathology regardless of species and exposure route expands our understanding of how SARS-CoV-2 infection may lead to ARDS and/or functional lung damage and demonstrates the near clinical response of the nonhuman primate model for anti-fibrotic therapeutic evaluation studies.
 
Back
Top Bottom